Table 1.
Clinicopathologic factors | Cases | x̄ ± s | t/F | P‐value |
---|---|---|---|---|
Breast sample | ||||
Normal breast | 30 | 1.45E‐04 ± 1.83E‐04 | –5.092 | 0.000 |
Breast cancer | 108 | 1.08E‐02 ± 2.15E‐02 | ||
Tumor size (cm) | ||||
≤2 | 50 | 7.95E‐03 ± 1.59E‐02 | 0.970 | 0.382 |
2–5 | 50 | 1.38E‐02 ± 2.69E‐02 | ||
>5 | 8 | 8.37E‐03 ± 1.01E‐02 | ||
Lymph node status | ||||
Negative | 52 | 4.65E‐03 ± 9.11E‐03 | 2.995 | 0.004 |
Positive | 56 | 1.63E‐02 ± 2.75E‐02 | ||
Lymph node positive number | ||||
0 | 52 | 4.65E‐03 ± 9.11E‐03 | 3.811 | 0.012 |
1–3 | 22 | 2.00E‐02 ± 2.89E‐02 | ||
4–9 | 15 | 1.92E‐02 ± 3.29E‐02 | ||
≥10 | 19 | 9.71E‐03 ± 2.08E‐02 | ||
Clinical stage | ||||
I | 15 | 1.24E‐02 ± 1.81E‐02 | 0.475 | 0.700 |
II | 67 | 8.90E‐03 ± 1.97E‐02 | ||
III | 22 | 1.50E‐02 ± 2.93E‐02 | ||
IV | 4 | 1.04E‐02 ± 1.48E‐02 | ||
Nuclear grade † | ||||
I | 12 | 8.91E‐03 ± 1.61E‐02 | 0.774 | 0.464 |
II | 73 | 9.41E‐03 ± 1.92E‐02 | ||
III | 23 | 1.56E‐02 ± 2.98E‐02 | ||
ER ‡ | ||||
Positive | 67 | 1.31E‐02 ± 2.63E‐02 | 2.209 | 0.030 |
Negative | 37 | 5.61E‐03 ± 6.68E‐03 | ||
Missing | 4 | |||
PR ‡ | ||||
Positive | 46 | 1.50E‐02 ± 2.84E‐02 | 1.835 | 0.071 |
Negative | 58 | 6.71E‐03 ± 1.32E‐02 | ||
Missing | 4 | |||
Her2 § | ||||
Positive | 28 | 1.05E‐02 ± 2.15E‐02 | 0.345 | 0.731 |
Negative | 55 | 9.03E‐03 ± 1.81E‐02 | ||
Missing | 25 | |||
Relapse or distant metastasis | ||||
Negative | 54 | 7.52E‐03 ± 1.22E‐02 | 0.938 | 0.359 |
Positive | 19 | 1.33E‐02 ± 2.59E‐02 | ||
Less than 3 years follow up | 35 |
Grade I nuclei indicates well‐differentiated breast cells that generally appear normal; Grade III shows poorly differentiated breast cells that do not appear normal; and Grade II has characteristics between Grade I and Grade III tumors with moderately differentiated breast cells.
Positive when more than 15% of the membrane showed staining by immunohistochemical staining.
Positive when more than 10% of the nuclei showed staining by immunohistochemical staining.